OptiNose, Inc. (OPTN) EPS Estimated At $-0.74

May 17, 2018 - By Robert Crowder

Analysts expect OptiNose, Inc. (NASDAQ:OPTN) to report $-0.74 EPS on June, 12.After having $-0.64 EPS previously, OptiNose, Inc.’s analysts see 15.63 % EPS growth. The stock decreased 4.51% or $1.16 during the last trading session, reaching $24.58. About 597,935 shares traded or 545.79% up from the average. OptiNose, Inc. (NASDAQ:OPTN) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company has market cap of $931.81 million. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It currently has negative earnings. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.

More notable recent OptiNose, Inc. (NASDAQ:OPTN) news were published by: Nasdaq.com which released: “Optinose CEO Peter Miller and President/COO Ramy Mahmoud Named EY Entrepreneur of the Year 2018 Finalists in …” on April 23, 2018, also Nasdaq.com with their article: “Optinose Reports First Quarter 2018 Financial Results and Recent Operational Highlights” published on May 14, 2018, Digitaljournal.com published: “OptiNose, Inc. to Host Earnings Call” on May 14, 2018. More interesting news about OptiNose, Inc. (NASDAQ:OPTN) were released by: Benzinga.com and their article: “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” published on May 16, 2018 as well as Streetinsider.com‘s news article titled: “Optinose (OPTN) PT Raised to $30 at BMO Capital” with publication date: May 15, 2018.

OptiNose, Inc. (NASDAQ:OPTN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: